MedPath

A program for ALS Care in Europe

Completed
Conditions
Amyotropic Lateral Sclerosis (ALS) muscle disease
10029317
Registration Number
NL-OMON46176
Lead Sponsor
divisie hersenen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
120
Inclusion Criteria

In order to be eligible to participate in this study, a patient (age > 18 years) must meet all of the following criteria: Possible, Probable, Laboratory Supported Probably and Definite ALS according to the El Escorial Criteria.Caregivers have to be older than 18 years.

Exclusion Criteria

Patients who are impaired to the extent that they cannot complete an informed consent process are excluded from participation in the study.
Patients who already participate in study 16-273 (NL56989.041.16)

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Effectiveness of the ALS-healthcare programme for patients and caregivers will<br /><br>be evaluated using QoL, distress and cost effectiveness measures.<br /><br>McGill quality of life questionnaire, the Schedule for the Evaluation of<br /><br>Individual Quality of Life (SeiQoL) and 5Q-5D-5L, and anxiety and depression<br /><br>(Hospital Anxiety and Depression scale).<br /><br><br /><br>Additionally, for a subset of patients and caregivers an exploratory nested<br /><br>study (N=25) will be conducted which includes detailed quality of life<br /><br>assessments including existential domains, attitudes to end of life, advance<br /><br>directives and decision-making and meaning of life developed by the Munich<br /><br>ALS-CarE partners will be applied. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Correlates of QoL, anxiety, depression and caregiver burden with ALS severity<br /><br>which will be measured with ALS-FRS-R, Mitos and Kings staging, Edinburgh<br /><br>Cognitive ALS screen (ECAS), Vital Capacity and Sniff Nasal Inspiratory<br /><br>Pressure (SNIP) (part 3 of the data collection for patients).</p><br>
© Copyright 2025. All Rights Reserved by MedPath